Operationally, cash flow from operations rose to Rs 118 crore, up from Rs 96 crore in Q1 FY25, a 22.9% YoY increase.

Compared to Q4 FY25, revenue from operations grew by 1.5%, and total revenue improved by 1.0%. Gross profit increased by 4.6%, while EBITDA rose 3.7% QoQ. Profit before tax increased 4.4% sequentially, and PAT saw a 3.8% rise, reflecting continued earnings momentum.

The company continues to derive the bulk of its revenue from international markets, with 79% coming from emerging markets like Latin America and Africa, and the remaining 21% from the United States.

C.C. Paarthipan, chairman said: 'We’re putting in place the right building blocks for both Emerging Markets and Regulated markets. We're making good progress with finalizing partners and also filing dossiers in our new key target markets of Mexico, Chile, USA etc. We're also aiming to gradually onshore some strategic manufacturing at important locations in Latin America and US, and taking the first steps of acquiring land/buildings for the same. We've also launched our second innings from China which will focus more deeply on high-tech products like Biosimilars, Peptides etc. We're strengthening our Marketing and Regulatory teams at both India and LatAm with seasoned professionals, to ensure our growth momentum remains steady. We continue to have a sharp focus on consolidating our presence in the existing markets with expansion on products, profits and cashflows.'

Caplin Point Laboratories is a pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. The company also has a growing presence in the regulated markets such as US through its subsidiary Caplin Steriles and Caplin Steriles USA Inc.